Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: Accumulating evidence for synergy, efficacy, and safety

Medical Oncology

Volumn 23, Issue 2, 2006, Pages 147-160

  Pentheroudakis, G ^a   Razis, E ^b   Athanassiadis, A ^c   Pavlidis, N ^a   Fountzilas, G ^d  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b Ygeia Hospital   (Greece)

^c GENERAL HOSPITAL OF LARISSA   (Greece)

^d PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

Breast cancer; Carboplatin; Chemotherapy; Paclitaxel

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CISPLATIN; CREMOPHOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; GEFITINIB; GEMCITABINE; GLYCOPROTEIN P; NAVELBINE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; ALLERGIC REACTION; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHRONOPHARMACOLOGY; CHRONOTHERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; CROSS RESISTANCE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HEALTH CARE COST; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MEDICAL PARAMETERS; METASTASIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PERFORMANCE; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SALVAGE THERAPY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM METASTASIS; PACLITAXEL;

EID: 33646857683     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:2:147     Document Type: Review

References (57)

1. American Cancer Society. Cancer Facts and Figures 2003. Atlanta, GA: American Cancer Society;2003:http://www.cancer.org/downloads/STT/ CAFF2003PWSecured.pdf.
2. Mincey BA, Perez EA. Concise review for clinicians: advances in screening, diagnosis and treatment of breast cancer. Mayo Clin Proc 2004;79:810-816.
3. Perez EA. Paclitaxel in breast cancer. The Oncologist 1998;3:373-389.
4. Gianni L, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumour efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688-2699.
5. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58.
6. Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
7. Buzdar AU, et al. Significantly higher pathological complete remission rate following neoadjuvant therapy with transtuzumab, paclitaxel and anthracycline-containing chemotherapy: initial results of a randomized trial in operable breast cancer with HER2 positive disease. Proc Am Soc Clin Oncol 2004;23:7(abstr 520).
8. Valero V, et al. Normal cardiac biopsy results following co-administration of doxorubicin, cyclophosphamide, and transtuzumab to women with HER2 positive metastatic breast cancer. Proc Am Soc Clin Oncol 2004;23:20(abstr 572).
9. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409-422.
10. Martin M, et al. Carboplatin: an active drug in metastatic breast cancer. J Clin Oncol 1992;10:433-437.
11. O Brien ME, Talbot DC, Smith IE. Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 1993;11:2112-2117.
12. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997;48:353-374.
13. Long BH, Fairchild CR. Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telophase. Cancer Res 1994;54:4355-4361.
14. Donaldson KL, Goolsby GL, Wahl AF. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 1994;57:847-855.
15. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001; 7:2168-2181.
16. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990;40:2353-2362.
17. Liebmann JE, Fisher J, Teague D, Cook JA. Sequence dependence of paclitaxel combined with cisplatin or alkylators in human cancer cells. Oncol Res 1994;6:25-31.
18. Konecny G, et al. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples. Breast Cancer Res Treat 2001;67:223-233.
19. Vanhoefer U, et al. Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 1995;31A(1):92-97.
20. Fujimoto S, Chikazawa H. Schedule-dependent and independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo. Jpn J Cancer Res 1998;89:1343-1351.
21. Parker RJ, et al. Influence of taxol:ciplatin sequencing on cisplatin-DNA adduct repair in human ovarian cancer cells. Proc Am Assoc Cancer Res 1993;34:356.
22. Milross CJ, et al. Sequence-dependent antitumor activity of paclitaxel and cisplatin in vivo. Int J Cancer 1995;62:599-604.
23. Huizing MT, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small cell lung cancer. J Clin Oncol 1997;15:317-329.
24. Calvert AH, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756.
25. Calvert AH, et al. Carboplatin in combination with paclitaxel in advanced ovarian cancer: Dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 1995;22(suppl 12): 91-98.
26. Belani CP, et al. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small cell lung cancer. J Clin Oncol 1999;17:676-684.
27. Pertussini E, Ratacjak J, Majka M, Vaughn D, Ratacjak MZ, Gewirtz AM. Investigating the platelet-sparing mechanism of paclitaxel-carboplatin combination chemotherapy. Blood 2001;97:638-644.
28. Rowinsky EK, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991;9:1692-1703.
29. Huizing MT, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993;11:2127-2135.
30. Gianni L, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180-190.
31. Janinis J, et al. Pegylated liposomal doxorubicin hydrochloride and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by HECOG. Anticancer Drugs 2004;15(5):479-487.
32. Van Zuylen L, et al. Interrelationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients. Anticancer Drugs 2000;11:331-337.
33. Gelderblom H, et al. Comparative pharmacokinetics of unbound paclitaxel during 1 and 3-hour infusions. J Clin Oncol 2002;20:574-581.
34. Van Warmerdam LJC, et al. Can the serum creatinine level be used to calculate the optimal dosage of carboplatin? Proceedings of the 7th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Amsterdam, The Netherlands, March 1-4, 1995 (abstract 65).
35. Fountzilas G, et al. Paclitaxel by 3-hour infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group. Eur J Cancer 1997;33:1893-1895.
36. Fountzilas G, et al. First-line chemotherapy with paclitaxel by 3-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by HECOG. Ann Oncol 1998;9:1031-1034.
37. Perez EA, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000;88:124-131.
38. Seidman A, et al. CALGB 9840: phase III study of weekly paclitaxel via a 1-hour infusion versus standard 3-hour infusion every third week in the treatment of metastatic breast cancer with transtuzumab for HER2 positive metastatic breast cancer and randomized for transtuzumab in HER2 normal metastatic breast cancer. Proc Am Soc Clin Oncol 2004;23(suppl):14 (abstract 512).
39. Loesch D, et al. Phase II multicentre trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol 2002;20:3857-3864.
40. Fountzilas G, et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients. with advanced breast cancer: a phase III study conducted by HECOG. Ann Oncol 2004;15:1517-1526.
41. Fountzilas G, et al. Paclitaxel, carboplatin and gefitinib (Iressa, ZD1839) as first-line chemotherapy in patients with advanced breast cancer: a phase II study. Breast Cancer Res Treat 2003;82(suppl 1):S85.
42. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-1838.
43. Pegram MD, Konecny GE, O Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of transtuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-749.
44. Merlin JL, Barberi-Heyob M, Bachmann N. In vitro comparative evaluation of transtuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2 expressing human breast cancer cell lines. Ann Oncol 2002;13:1743-1748.
45. Burris H, et al. Phase II trial of transtuzumab followed by weekly paclitaxel/carboplatin as first-line treatment of patients with metastatic breast cancer. J Clin Oncol 2004;22:1621-1629.
46. Perez EA, et al. N98-32-52: efficacy and tolerability of two schedules of paclitaxel, carboplatin and transtuzumab in women with HER2-positive metastatic breast cancer: a North Central Cancer Treatment Group randomized phase III trial. Breast Cancer Res Treat Rep 2000;82(suppl 1):547.
47. Robert N, et al. Phase III study of transtuzumab, paclitaxel and carboplatin versus transtuzumab and paclitaxel in women with HER2 overexpressing metastatic breast cancer: an update including survival. Proc Am Soc Clin Oncol 2004;23:20s.
48. Dy GK, Adjei AA. Novel targets for lung cancer therapy:part I. J Clin Oncol 2002;20:2881-2894.
49. Shepherd FA, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc Am Soc Clin Oncol 2004;23(suppl):12. (Abstract 7022).
50. Johnson DH. Gefitinib (Iressa) trials in non-small cell lung cancer. Lung Cancer 2003;41:S23-S28.
51. Miller VA, et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small cell lung cancer. J Clin Oncol 2003;21:2094-2100.
52. Sirotnak FM, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-4892.
53. Giaccone G, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004;22:777-784.
54. Herbst RS, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004;22:785-794.
55. Herbst RS, et al. TRIBUTE - a phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;23:617 (Abstract 701).
56. Herbst RS, et al. Subset analysis of INTACT results for gefitinib (ZD-1839) when combined with platinum-based chemotherapy (CT) for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003;22:627 (Abstract 252).
57. Lynch TJ, et al. Activating mutations of the epidermal growth factor receptor underlying the responsiveness of NSCLC to gefitinib. N Engl J Med 2004;350:2129-2139.